Ruth Sheehan

Ms. Ruth Sheehan


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
PCPatrick Crowley
Patrick Crowley
AHAlasdair L. Henry
Alasdair L. Henry
MOMary ODonovan
Mary ODonovan
RSRuth Sheehan
Ruth Sheehan
EFEvelyn Flanagan
Evelyn Flanagan
Rónán O'CaoimhRónán O'Caoimh
Rónán O'Caoimh
Dementia is a leading and growing cause of disability worldwide. Insomnia is highly prevalent in mild cognitive impairment (MCI) and dementia and is associated with impaired cognition, functional decline, and reduced quality of life (QoL). Although sleep disturbance represents a potentially modifiable risk factor within the trajectory of cognitive impairment, there have not been many studies conducted to examine the feasibility or preliminary efficacy of digital cognitive behavioural therapy for insomnia (dCBT-I) in this population. The aim of this pilot randomised controlled feasibility study is to evaluate the acceptability, adherence, and potential clinical effects of a multi-component dCBT-I programme (Sleepio) in adults with MCI or mild dementia and comorbid insomnia. Thirty community-dwelling adults aged ≥50 years with established MCI or mild dementia (Mini-Mental State Examination ≥18; Clinical Dementia Rating 0.5–1.0) and insomnia (Sleep Condition Indicator ≤16) will be randomised (1:1) to Sleepio or a wait-list control. Feasibility outcomes include recruitment and retention rates, intervention adherence (completion of ≥4/6 sessions), and acceptability measured using validated usability scales. Secondary outcomes include changes in sleep, mood, QoL, cognition, and function over 10 weeks. Adverse events will be monitored to assess safety. Findings will inform the design of a future definitive trial evaluating digital sleep interventions in cognitively impaired populations. Ethical approval has been granted. The trial is registered at ClinicalTrials.gov (NCT07363928).

3 November 2026 in Clocks & Sleep
Verified
Journal Article
Open access
PDF file
PCPatrick Crowley
Patrick Crowley
MOMary ODonovan
Mary ODonovan
RSRuth Sheehan
Ruth Sheehan
EFEvelyn Flanagan
Evelyn Flanagan
AHAlasdair L. Henry
Alasdair L. Henry
Rónán O'CaoimhRónán O'Caoimh
Rónán O'Caoimh
Insomnia and dementia are major public health issues. Although cognitive behavioural therapy for insomnia (CBT-I) is the recommended first line treatment for insomnia, few studies have examined its usability or effectiveness in people with cognitive impairment. Digital CBT-I (dCBT-I) is an effective and easily accessible alternative to CBT-I. We undertook a mixed-methods analysis of the usability and acceptability of dCBT-I (SleepioTM) in patients attending a memory clinic. Participants were community dwellers aged ≥50 years with insomnia (Sleep Condition Indicator score ≤ 16) and subjective cognitive decline (SCD), mild cognitive impairment (MCI) or dementia. The Mobile Device Proficiency Questionnaire (MDPQ) assessed digital literacy. The System Usability Score (SUS) and Usability Metric for User Experience–Lite (UMUX-Lite) assessed usability. Acceptability was assessed by analysing adherence to the intervention and subjective reports of perceived benefit. Both usability and acceptability were further explored in semi-structured interviews. Among 24 participants (median age 69; 17 females), 2 had SCD, 14 MCI, and 8 dementia. Overall response to SleepioTM was positive. Participants favoured relaxation-based aspects of the programme. Behavioural elements, such as sleep restriction, were generally less favoured. Lack of digital literacy was the main barrier to engagement, though this could be surmounted by assistance from caregivers or family members in certain instances. Regardless of cognitive status, those with above-average digital literacy (MDPQ > 20) undertook a median 6/6 sessions, while those with below-average digital literacy (MDPQ < 20) undertook a median 3/6 sessions. Among those with above-average digital literacy, median SUS and UMUX-Lite were 72.5 and 75, respectively, representing acceptable usability, while overall scores were 63.75 and 56.25, respectively, representing marginally acceptable usability. Our findings may suggest that SleepioTM is usable and acceptable for people with SCD, MCI and selected individuals with mild dementia, particularly where digital literacy is preserved. Additional caregiver support may facilitate usability among people with MCI and lower digital literacy. Usability appears limited in more advanced dementia. However, as some subgroups were small, more research is required to confirm these findings.